[1] |
Ge Jing, Wang Jun, He Yuqi, Nie Wenjuan.
Six cases of pseudomembranous colitis caused by anti-tuberculosis drugs and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1320-1326.
|
[2] |
Li Xuelian, Jing Wei, Wang Qingfeng, Chu Naihui, Nie Wenjuan.
An all-oral shortened regimen containing new drugs to treat MDR/rifampicin-resistant tuberculosis: three case reports and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1327-1334.
|
[3] |
Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua.
Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
|
[4] |
Ren Fei, Ma Jinbao, Li Rong, Yang Han, Yang Hong, Wu Yanqin, Yang Xinjun, Dang Liyun.
Efficacy and eligibility of high-dose moxifloxacin short-course regimen for rifampicin-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 52-59.
|
[5] |
Wang Ni, Huang Fei, Zhu Limei, Zeng Yi, Zhang Ruimei, Geng Hong, Liu Xuefa, Zheng Jiangang, Zong Peilan, Zeng Zhong, Li Jinlan, Cai Cui, Guo Xiaohong, Zhong Yin, Liu Li, Xie Yan, Du Fangfang, Zhou Lin, Cheng Shiming.
Implementation study on promoting the use of anti-tuberculosis fixed-dose combination in provincial and prefecture tuberculosis designated hospitals
[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 927-933.
|
[6] |
Jin Long, Wang Lihua, Zhang Xiaolei, Jiang Huailong, Li Xiaonan, Liu Yuqin.
Efficacy and safety of modified all-oral short course chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1321-1326.
|
[7] |
QI Xue-ting, LU Yu, CHEN Xiao-you.
Pharmacodynamic characteristics and interaction of new antituberculosis drugs
[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 965-969.
|
[8] |
MA Yan*, GAO Wei-wei.
Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be
[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317.
|
[9] |
DENG Guo-fang.
Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity
[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321.
|
[10] |
LIU Hai-ting, LU Yu.
Progress in pharmacodynamic screening of anti-tuberculosis drug combination
[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 404-408.
|
[11] |
HE Xiao-xin, LI Bo, ZHOU Lin.
Interpretation of Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1243-1247.
|
[12] |
LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, ZHANG Qing, SHA Wei.
Individualized treatment for retreatment smear-positive pulmonary tuberculosis patients based on molecular drug susceptibility testing and its short-term effectiveness
[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1010-1015.
|
[13] |
RUAN Hong-yun, LI Qi, CHEN Xiao-you, DUAN Hong-fei, GUO Chao, CAO Min, LIANG Qing-tao, WANG Zhi-ru, YANG Yang, SUN Gui-xin, LI Hua, DENG Ling, SHAO Ling-ling, XING Wei-xiang, ZHANG Yun, YANG Xin-ting.
Dynamic changes of lung function and hormone-assisted therapy in patients with tuberculous pleurisy
[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 58-65.
|
[14] |
ZHANG Kai-yi, LYU Zheng-xuan, LIU Yong-li, ZHANG Le, ZHU Jiang-chun, YU Ming-li.
A case of multisystemic disseminated infection caused by Mycobacterium abscess diagnostic and treatment process analysis
[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 66-71.
|
[15] |
YANG Min, FU Liang, DENG Guo-fang.
Progress in the treatment and management of tuberculosis complicated with diabetes
[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 87-90.
|